# US 2018/0021295 A1 · Methods and materials for assessing chemotherapy responsiveness and treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021295 A1
- Document ID: US20180021295A1
- Status: Published application
- Kind: A1
- Application number: 15/551,123
- Filed: 2016-02-17
- Published: 2018-01-25
- Earliest claimed: 2015-02-19
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Matthew P. Goetz; Judy C. Boughey; Liewei Wang; Krishna R. Kalari; Richard M. Weinshilboum; Vera J. Suman
- Web page: https://patentgrep.com/patent/US20180021295A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57515: of the breast
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method for treating cancer, wherein said method comprises:
(a) administering a USP2 inhibitor to a mammal having cancer, and
(b) administering a chemotherapeutic agent to said mammal.

### Claim 8 (depends on 7)

The method of claim 7, wherein said mammal is a human.

### Claim 9 (depends on 7)

The method of claim 7, wherein said cancer is breast cancer.

### Claim 10 (depends on 7)

The method of claim 7, wherein said mammal comprises a variant PKD1 allele.

### Claim 11 (depends on 10)

The method of claim 10, wherein said variant PKD1 allele is a G→A allele of rs148709380.

### Claim 12 (depends on 7)

The method of claim 7, wherein said USP2 inhibitor is NSC-632839 or a compound set forth in FIGS. 10A-G.

### Claim 13 (depends on 7)

The method of claim 7, wherein said chemotherapeutic agent is a taxane agent.
